Methods and compositions for treating polycystic ovary syndrome
First Claim
Patent Images
1. A method of treating a subject suffering from PCOS comprising the step of administering a GLP-1 molecule, wherein the subject exhibits at least one symptom of PCOS.
8 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to methods of treating polycystic ovary syndrome (PCOS) comprising administering glucagon-like peptide-1 (GLP-1) to subjects suffering therefrom.
-
Citations
18 Claims
-
1. A method of treating a subject suffering from PCOS comprising the step of administering a GLP-1 molecule, wherein the subject exhibits at least one symptom of PCOS.
-
2. The method according to embodiment 1, wherein the symptom is selected from the group consisting of insulin resistance, hyperinsulinemia, type-2 diabetes, obesity, hypertension, hyperlipidemia, anovulation or irregular ovulation, infertility, hyperandrogenism, hirsutism, alopecia, acne, enlarged multifollicular ovaries, abnormal uterine bleeding, and spontaneous abortion.
-
3. A method of reducing insulin resistance in a subject suffering from PCOS comprising the step of administering a GLP-1 molecule.
-
4. A method of preventing the onset of type-2 diabetes in a subject suffering from PCOS comprising the step of administering a GLP-1 molecule.
-
5. A method of restoring regular menses in a subject suffering from PCOS comprising the step of administering a GLP-1 molecule.
-
6. A method of restoring regular ovulation in a subject suffering from PCOS comprising the step of administering a GLP-1 molecule.
-
7. A method of restoring fertility in a subject suffering from PCOS comprising the step of administering a GLP-1 molecule.
-
8. A method for preventing spontaneous abortion in a subject suffering from PCOS comprising the step of administering a GLP-1 molecule.
-
9. The method according to any one of embodiments 1 to 8, wherein the subject is a human.
-
10. The method according to any one of embodiments 1 to 8, wherein the GLP-1 molecule is selected from the group consisting of GLP-1(7-36)NH2, GLP-4(7-37), and exendin-4.
-
11. The method according to any one of embodiments 1 to 8, wherein the GLP-1 molecule is selected from the group consisting of GLP-1(7-36)NH2 and GLP-1(9-36)NH2.
-
12. The method according to any one of embodiments 1 to 8 wherein the GLP-1 is administered by an infusion pump or by subcutaneous injection of a slow release formulation.
-
13. The method according to any one of embodiments 1 to 8 wherein the GLP-1 is coadministered with an agent selected from the group consisting of an ovulation inducing drug, an anti-androgenic drug, an insulin-sensitizing agent and glucose.
-
14. The method according embodiment 13 wherein the ovulation inducing drug is selected from the group consisting of clomiphene, follistim, and Gonal-F.
-
15. The method according to embodiment 13 wherein the anti-androgenic drug is selected from the group consisting of a birth control pill, spironolactone, flutamide, and finasteride.
-
16. The method according to embodiment 13 wherein the insulin-sensitizing agent selected from the group consisting of metformin, D-Chiro-inositol, diazoxide, and PPAR inhibitors (e.g., troglitazone (Rezulin), rosiglitazone (Avandia), and pioglitazone (Actos)).
-
17. The method according to embodiment 13, wherein the glucose is administered intravenously.
-
18. The method according to embodiment 13, wherein the GLP-1 and the agent are administered either sequentially or concurrently.
Specification